Identification of Mechanisms in the Erythroid Response in Patients With Myelodysplasia Undergoing Chelation Therapy
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 31 Jul 2019
Price : $35 *
At a glance
- Drugs Deferasirox (Primary) ; Deferoxamine (Primary)
- Indications Anaemia; Aplastic anaemia; Myelodysplastic syndromes; Myelofibrosis
- Focus Pharmacodynamics
- Acronyms BIOFER12
- 29 Jul 2019 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
- 21 Jun 2018 Planned End Date changed from 1 Jun 2018 to 1 Dec 2018.
- 21 Jun 2018 Status changed from recruiting to active, no longer recruiting.